Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.

@article{Du2007AnalogueIB,
  title={Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.},
  author={Q. Du and Shu-Qing Wang and K. Chou},
  journal={Biochemical and biophysical research communications},
  year={2007},
  volume={362 2},
  pages={
          525-31
        }
}
The worldwide spread of H5N1 avian influenza and the increasing reports about its resistance to the existing drugs have made a priority for the development of the new anti-influenza molecules. The crystal structure of H5N1 avian influenza neuraminidase reported recently by Russell et al. [R.J. Russell, L.F. Haire, D.J. Stevens, P.J. Collins, Y. P. Lin, G.M. Blackburn, A.J. Hay, S.J. Gamblin, J.J. Skehel, The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug… Expand
On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
TLDR
Two novel structures clearly suggest that it may be possible for a new substituent to be developed by functional modifications at position of the 4-amino group of oseltamivir in order to make polar contacts with the guanidinium side chain of Arg156, and thereby enhance the binding of a more potent inhibitor. Expand
Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
TLDR
The present work is a significant breakthrough in the discovery of potent group-1-specific neuraminidase inhibitors, which may be further investigated for the treatment of infection by the H5N1 virus. Expand
Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus.
TLDR
Three derivatives of neuraminidase show much stronger inhibition power than oseltamivir, and hence may become excellent candidates for developing new and more powerful drugs for treating influenza. Expand
Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
TLDR
It has been revealed that the hydrophobic residue Try347 in H5N1-NA does not match with the Hydrophilic carboxyl group of oseltamivir as in the case of H1N 1-NA, which may be the reason why H 5N1 avian influenza virus is drug-resistant to oselTamivIR. Expand
Binding mechanism of H5N1 influenza virus neuraminidase with ligands and its implication for drug design.
TLDR
It has been found that the compound AG7088 has better binding energy than zanamivir and oseltamivirs to the same receptor, respectively, and it was adopted as a template to perform the similarity search of 392,698 druggable compounds in order to find the leading candidates for the next step of modeling studies. Expand
Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus.
TLDR
Five oseltamivir analogs PMC-31-PMC-36, synthesised according to the outcomes of a rational design analysis, were screened for their inhibition against neuraminidase N1 and N3 and a dramatic reduction of activity was observed. Expand
The derivatives of oseltamivir design passing through the important cleft of neuraminidase against influenza virus by de novo design
Owing to its unique function to release the progeny virus particles from the surface of an infected cell, neuraminidase has drawn special attention for developing new drugs to treat influenzaExpand
The hydrophobic side chain of oseltamivir influences type A subtype selectivity of neuraminidase inhibitors
TLDR
The study of structure–activity relationships revealed that the C‐5 position amino group of oseltamivir was pointed to 150‐cavity of the neuraminidase in group 1, important for selectivity of inhibitors against N1 versus N2 NA. Expand
In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1
TLDR
The results showed that AD3BF2D ligand can be used as a good candidate for neuraminidase inhibitor to cope with influenza A virus subtype H1N1. Expand
In silico design of cyclic peptides as influenza virus, a subtype H1N1 neuraminidase inhibitor
TLDR
Based on molecular docking, new antiviral drug designs have been found that showed better activity and affinity than standard ligand to inhibit neuraminidase activity and DNY, NNY and LRL ligands have low toxicity and were predicted to have at least 59% possibility of being synthesized in wet laboratory experiment. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
TLDR
It may be possible to exploit the size and location of the group-1 cavity to develop new anti-influenza drugs, according to X-ray crystallography, which shows that these two groups of neuraminidases are structurally distinct. Expand
Structural studies of the resistance of influenza virus neuramindase to inhibitors.
TLDR
The sensitivity of neuraminidase variants E119G and R292K to BCX-1812 has been measured and found in both cases to be intermediate between those of zanamivir and oseltamivIR. Expand
Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases.
TLDR
The structure-activity relationship between NA (neuraminidase) and its three inhibitors (DANA, zanamivir, and oseltamivIR) was investigated and it was indicated that 11 functional residues were highly conserved except for AAF02313 with the mutated virus strain. Expand
Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors
TLDR
It is indicated that different patterns of susceptibility and cross-resistance between NA inhibitors may prove important if antiviral resistance to zanamivir and oseltamivIR were to emerge. Expand
Resistance of influenza viruses to neuraminidase inhibitors--a review.
Influenza virus is a negative stranded RNA virus. It contains two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). HA exists as a trimer and is responsible for binding to theExpand
Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
TLDR
The results suggest that the decreased affinity in enzyme from influenza B is directly correlated with the small changes that occur in the amino acid residue interactions accompanying ligand binding, and that this tendency is a useful descriptor for the prediction of inhibitor potency. Expand
Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor.
TLDR
The design, discovery, and development of oseltamivir as an oral therapeutic to treat influenza infection is summarized. Expand
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.
TLDR
The design, synthesis, and in vitro evaluation of the novel carbocycles as transition-state-based inhibitors of influenza neuraminidase (NA) are described and the presence of a large hydrophobic pocket in the region corresponding to the glycerol subsite of sialic acid is revealed. Expand
Analysis of inhibitor binding in influenza virus neuraminidase
TLDR
Replacement of the hydroxyl at the C9 position in DANA and 4‐amino‐DANA with an amine group, with the intention of taking advantage of an increased electrostatic interaction with a conserved acidic group in the active site to improve inhibitor binding, significantly reduces the inhibitor activity of both compounds. Expand
Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS☆
TLDR
It has been observed that both the above compounds interact with the active site of the SARS enzyme through six hydrogen bonds, which may provide a solid basis for subsite analysis and mutagenesis relative to rational design of highly selective inhibitors for therapeutic application. Expand
...
1
2
3
4
5
...